weight loss drug news today glp-1 september 2025 FDA takes aim at telehealth companies for promoting unofficial dupes Lilly hikes revenue forecasts on

Novo Nordisks Wegovy (semaglutide), the first and only once-weekly GLP-1 receptor agonist approved for weight management in people with obesity, has been found to help patients lose up to 15 percent of their body weight in over 68 weeks

Efinopegdutide Emerging data on novel agents continue to expand the evidence base

(941) 957-0200 * Disclaimer - Outcomes depend on multiple factors including adherence to physician-directed nutrition, physical activity, medical supervision, and individual health status

Pharmacol Rep (2016) 68(2):32937

NYC Non-Surgical Weight Loss Read More About: ESG vs Ozempic: Own Your Weight Loss or Rent It

Authors Contribution All authors contributed significantly to the conception, design, analysis, and writing of this manuscript